Nanomedicine News RSS Feed - Nanomedicine

New Book on Bio-Inspired Nanomaterials and Devices

New Book on Bio-Inspired Nanomaterials and Devices

Nanomedicine has been developing rapidly in recent years, particularly in the development of novel nano tools for medical diagnosis and treatment. For instance, a new trend is becoming prevalent in developing nanosystems for simultaneous tumor diagnosis and therapy. [More]
Tekmira Commences Dosing in TKM-HBV Phase I Clinical Trial for Chronic Hepatitis B Virus Infection

Tekmira Commences Dosing in TKM-HBV Phase I Clinical Trial for Chronic Hepatitis B Virus Infection

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced today that it has dosed the first subject in a Phase I clinical trial of TKM-HBV, a therapeutic agent designed to reduce hepatitis B surface antigen in patients chronically infected with hepatitis B virus (HBV). [More]
Non-Functionalised Carbon Nanotubes May Not Be Blood-Compatible

Non-Functionalised Carbon Nanotubes May Not Be Blood-Compatible

Scientists in the School of Pharmacy and Pharmaceutical Sciences in Trinity College Dublin, have made an important discovery about the safety issues of using carbon nanotubes as biomaterials which come into contact with blood. The significance of their findings is reflected in their paper being published as the feature story and front page cover of the international, peer-reviewed journal Nanomedicine. [More]
MU Researcher Honored with Hevesy Medal for Contributions to Nanomedicine

MU Researcher Honored with Hevesy Medal for Contributions to Nanomedicine

Gold nanoparticles have been proven useful in a number of medical applications. Scientists are developing nanoparticles to produce pharmaceuticals used in the imaging and diagnosis of diseases such as cancer, arthritis, Parkinson's disease and eye degeneration. [More]
FDA Grants Fast Track Status for Celator’s CPX-351 to Treat Elderly Patients with Secondary AML

FDA Grants Fast Track Status for Celator’s CPX-351 to Treat Elderly Patients with Secondary AML

Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary Acute Myeloid Leukemia (AML). [More]
New, Wearable Nanowire Sensor Monitors Electrophysiological Signals

New, Wearable Nanowire Sensor Monitors Electrophysiological Signals

Researchers from North Carolina State University have developed a new, wearable sensor that uses silver nanowires to monitor electrophysiological signals, such as electrocardiography (EKG) or electromyography (EMG). [More]
Newly Designed Nanoparticle Can Be Detected By Six Medical Imaging Techniques

Newly Designed Nanoparticle Can Be Detected By Six Medical Imaging Techniques

It's technology so advanced that the machine capable of using it doesn't yet exist. [More]
MIT Researchers Develop Novel Approach for Nanoscale Resolution Microscopy of Large Biological Samples

MIT Researchers Develop Novel Approach for Nanoscale Resolution Microscopy of Large Biological Samples

Researchers from MIT have successfully discovered a technique to physically magnify tissue samples by implanting them in a polymer, which swells on addition with water to enable high-resolution images. Since the late 1500s when the first microscope was invented, scientists have been devising ways to study preserved tissues and cells in a better manner. [More]
Tiny Microfluidic Device Helps Analyze Behavior of Blood from Sickle Cell Disease Patients

Tiny Microfluidic Device Helps Analyze Behavior of Blood from Sickle Cell Disease Patients

Patients with sickle cell disease often suffer from painful attacks known as vaso-occlusive crises, during which their sickle-shaped blood cells get stuck in tiny capillaries, depriving tissues of needed oxygen. Blood transfusions can sometimes prevent such attacks, but there are currently no good ways to predict when a vaso-occlusive crisis, which can last for several days, is imminent. [More]
Cerulean’s CRLX10 Nanoparticle-Drug Conjugate Phase 1b/2 Data Presented at ASCO 2015 Symposium

Cerulean’s CRLX10 Nanoparticle-Drug Conjugate Phase 1b/2 Data Presented at ASCO 2015 Symposium

Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced that preclinical data and initial clinical data from a Phase 1b/2 investigator-sponsored trial of CRLX101 in combination with chemoradiotherapy in non-metastatic rectal cancer was presented at the ASCO 2015 Gastrointestinal Cancers Symposium held January 15-17, 2015. [More]
Site Sponsors
  • Strem Chemicals - Nanomaterials for R&D
  • Park Systems - Manufacturer of a complete range of AFM solutions